SCM
KALV

Silverarc Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Silverarc Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-290,600
Closed -$4.69M – 79
2025
Q4 		$4.69M Buy
+290,600
New +$3.85M 0.65% 41
2024
Q1 		– Sell
-180,400
Closed -$2.21M – 87
2023
Q4 		$2.21M Sell
180,400
-350,000
-66% -$3.18M 0.66% 45
2023
Q3 		$5.11M Buy
+530,400
New +$5.42M 1.55% 27

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Silverarc Capital Management's KALV Position: Q1 2026 in Review

Silverarc Capital Management increased its KalVista Pharmaceuticals (KALV) stake by 19% in Q1 2026, buying an estimated $7.24M and bringing the position to 2,876,407 shares worth $57.9M. The position accounts for 5.91% of the portfolio, ranked #2.

Silverarc Capital Management first reported a position in KALV in Q1 2021 and has held it in 15 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Silverarc Capital Management held 2,876,407 shares of KalVista Pharmaceuticals worth $57.9M as of Q1 2026.
  • Silverarc Capital Management bought 449,289 KalVista Pharmaceuticals shares in Q1 2026, an estimated $7.24M.
  • KalVista Pharmaceuticals made up 5.91% of Silverarc Capital Management's portfolio in Q1 2026, its #2 holding.
  • Silverarc Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2021 and has held it in 15 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.